Copper Rock Capital Partners LLC grew its holdings in Charles River Laboratories Intl. Inc (NYSE:CRL) by 3.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 304,556 shares of the medical research company’s stock after acquiring an additional 10,546 shares during the period. Charles River Laboratories Intl. accounts for approximately 2.1% of Copper Rock Capital Partners LLC’s holdings, making the stock its 18th largest position. Copper Rock Capital Partners LLC’s holdings in Charles River Laboratories Intl. were worth $33,422,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of CRL. Schwab Charles Investment Management Inc. grew its position in Charles River Laboratories Intl. by 1.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 267,203 shares of the medical research company’s stock worth $27,028,000 after acquiring an additional 4,865 shares in the last quarter. Legal & General Group Plc grew its position in Charles River Laboratories Intl. by 26.1% in the second quarter. Legal & General Group Plc now owns 39,832 shares of the medical research company’s stock worth $4,029,000 after acquiring an additional 8,254 shares in the last quarter. American Century Companies Inc. bought a new stake in Charles River Laboratories Intl. in the second quarter worth approximately $292,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Charles River Laboratories Intl. by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in Charles River Laboratories Intl. by 4.7% in the second quarter. Principal Financial Group Inc. now owns 198,900 shares of the medical research company’s stock worth $20,119,000 after acquiring an additional 8,912 shares in the last quarter. 95.80% of the stock is owned by institutional investors.

Several analysts have commented on the stock. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Tuesday, October 24th. Credit Suisse Group reissued a “neutral” rating and issued a $112.00 target price (up from $95.00) on shares of Charles River Laboratories Intl. in a research report on Monday, October 16th. Jefferies Group boosted their target price on shares of Charles River Laboratories Intl. from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Royal Bank of Canada assumed coverage on shares of Charles River Laboratories Intl. in a research report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 target price for the company. Finally, Argus assumed coverage on shares of Charles River Laboratories Intl. in a research report on Wednesday, December 13th. They issued a “buy” rating and a $120.00 target price for the company. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $112.36.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the company’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Also, Director Robert J. Bertolini sold 3,609 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $110.22, for a total transaction of $397,783.98. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 10,500 shares of company stock valued at $2,885 and sold 1,064,673 shares valued at $2,876,056. 2.20% of the stock is currently owned by insiders.

Shares of Charles River Laboratories Intl. Inc (CRL) traded up $0.01 during trading on Monday, hitting $111.89. 181,715 shares of the stock were exchanged, compared to its average volume of 298,420. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. Charles River Laboratories Intl. Inc has a twelve month low of $77.61 and a twelve month high of $119.05. The firm has a market capitalization of $5,298.81, a PE ratio of 27.29, a price-to-earnings-growth ratio of 1.64 and a beta of 0.88.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The business had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the previous year, the company earned $1.18 earnings per share. Charles River Laboratories Intl.’s revenue for the quarter was up 9.0% on a year-over-year basis. equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 5.14 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/charles-river-laboratories-intl-inc-crl-shares-bought-by-copper-rock-capital-partners-llc/1799074.html.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with Analyst Ratings Network's FREE daily email newsletter.